Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
How Phosphate Becomes a Signaling Readout
2026-11-16
Phosphate is not best understood as a single receptor ligand with one characteristic affinity. Its scientific meaning depends on whether it is being transferred during phosphorylation, incorporated into ATP or nucleic acids, present as free inorganic phosphate, or tracked through phosphate-containing metabolites. These distinctions explain why kinase assays, phosphoproteomics, signaling studies, and metabolic flux analyses produce different kinds of evidence.
How UK-5099 Links Pyruvate Transport to Energy Readouts
2026-11-16
UK-5099, also known as PF-1005023, is documented as a mitochondrial pyruvate carrier inhibitor. Its reported effects connect mitochondrial pyruvate entry with respiration, cellular adenine-nucleotide balance, and glucose tolerance, while the different readouts should not be treated as interchangeable evidence.
How to Interpret Flufenamic Acid Channel Claims
2026-11-15
A channel-activation description identifies a useful mechanistic starting point, but it does not by itself establish a cellular, neuronal, or inflammatory outcome. The key interpretive task is to distinguish molecular identity, ion movement, membrane signaling, and downstream biological readouts.
What Multiplex CRISPR Evidence Actually Shows
2026-11-14
A literature-focused analysis of multiplex CRISPR–Cas explains how simultaneous targeting enables combinatorial gene disruption, structural-variant modeling and epigenetic regulation, while emphasizing the unresolved trade-offs involving DNA damage, specificity, delivery and translational relevance.
What Dual-Target CAR-T Comparisons Actually Show
2026-11-13
A preclinical comparison of a dual-target CAR-T platform in non-small-cell lung cancer links broader antigen recognition with more consistent tumor control and altered T-cell metabolic features. The evidence is encouraging but remains bounded by model-specific antigen measurements, small animal groups, surrogate readouts, and the absence of clinical validation.
How DPP-4 Inhibition Shapes Incretin Signaling
2026-11-13
Sitagliptin’s documented role as a selective DPP-4 inhibitor can be understood as a sequence linking enzyme inhibition to incretin persistence, intracellular signaling, and metabolic readouts. The strength of that interpretation depends on which biological level is measured and whether DPP-4-independent effects are also involved.
What Does 7,12-Diketolithocholic Acid Indicate?
2026-11-12
A measured change in 7,12-diketolithocholic acid is best interpreted as a readout of host–gut microbiota bile acid co-metabolism, not as a standalone diagnostic signal. Its biological meaning depends on formation, downstream conversion, transport, and the compartment in which it is measured.
HNRNPU Lactylation and Proteasome Controls
2026-11-12
A 2026 study connects HNRNPU K181 lactylation to PHGDH regulation, serine metabolism, and cervical-cancer growth. The findings support a metabolic RNA-regulatory mechanism, but they do not establish that proteasome inhibition drives the pathway or that (R)-MG132 is a mechanistic probe for it.
How Dual Protection Shapes Lysine Reactivity
2026-11-11
Fmoc-Lys(Boc)-OH is a protected lysine derivative designed to distinguish the alpha- and side-chain amino groups. Its dual-protection architecture explains selective amino group protection in peptide synthesis, while the documented identity and purity measurements support material characterization rather than coupling performance or biological activity.
How to Interpret Telotristat in Serotonin Research
2026-11-11
Telotristat is described as a TPH inhibitor and active metabolite of LX1606. This article explains how that molecular claim relates to serotonin biosynthesis, why biochemical and physiological readouts can diverge, and which conclusions remain limited to mechanism rather than demonstrated biological performance.
From DPP-4 Inhibition to Incretin Readouts
2026-11-10
How sitagliptin’s documented DPP-4 inhibition connects enzyme activity with incretin stability, intracellular signaling, and metabolic research readouts—and where that interpretation remains limited.
Context Determines What a Signaling Result Means
2026-11-10
A CCR7–Notch1 study in MMTV-PyMT mammary cancer cells shows why genotype, cell state, assay choice, and biological scale determine what a signaling result can support. The findings strengthen a mechanistic model of stem-like behavior while leaving therapeutic and clinical implications provisional.
How Bupranolol Changes Adrenergic Readouts
2026-11-09
Bupranolol is described as a competitive, non-selective beta-adrenergic receptor antagonist without intrinsic sympathomimetic activity. Understanding how that receptor-level action propagates through beta-adrenergic receptor signaling helps distinguish direct receptor effects from downstream changes in cAMP, contractility, and other cardiovascular measurements.
CLBRP Nanomedicine: Mechanism and Evidence
2026-11-09
Liu and colleagues describe a calcium lactate nanoparticle that combines bufalin delivery with CD47-directed CRISPR/Cas9 ribonucleoprotein delivery to connect tumor-cell death, macrophage reprogramming, and antitumor immunity. The study presents a coherent preclinical mechanism, but its strongest evidence remains model-specific and does not yet establish clinical efficacy, durable gene-editing safety, or the independent contribution of each component.
How Should Native His-Tag Capture Be Interpreted?
2026-11-08
Native His-tag protein purification demonstrates a selective nickel–histidine binding event and can support recovery of recombinant protein, but capture and reported capacity do not by themselves establish purity, folding, biological activity, or structural suitability.